Sangamo Therapeutics Stock Buy Hold or Sell Recommendation
| SGMO Stock | USD 0.49 0.03 5.12% |
Given the investment horizon of 90 days and your conservative attitude towards risk, our recommendation regarding Sangamo Therapeutics is 'Strong Sell'. Macroaxis provides Sangamo Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SGMO positions. The advice algorithm takes into account all of Sangamo Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Sangamo Therapeutics' buy or sell advice are summarized below:
Real Value 0.5 | Target Price 6.58 | Hype Value 0.52 | Market Value 0.49 | Naive Value 0.37 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Sangamo Therapeutics given historical horizon and risk tolerance towards Sangamo Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Sangamo Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Sangamo |
Execute Sangamo Therapeutics Buy or Sell Advice
The Sangamo recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Sangamo Therapeutics. Macroaxis does not own or have any residual interests in Sangamo Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Sangamo Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Sangamo Therapeutics Trading Alerts and Improvement Suggestions
| Sangamo Therapeutics is way too risky over 90 days horizon | |
| Sangamo Therapeutics has some characteristics of a very speculative penny stock | |
| Sangamo Therapeutics appears to be risky and price may revert if volatility continues | |
| Sangamo Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 176.23 M. Net Loss for the year was (257.83 M) with loss before overhead, payroll, taxes, and interest of (138.6 M). | |
| Sangamo Therapeutics currently holds about 315.72 M in cash with (224.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 57.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene Cell Therapy |
Sangamo Therapeutics Returns Distribution Density
The distribution of Sangamo Therapeutics' historical returns is an attempt to chart the uncertainty of Sangamo Therapeutics' future price movements. The chart of the probability distribution of Sangamo Therapeutics daily returns describes the distribution of returns around its average expected value. We use Sangamo Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Sangamo Therapeutics returns is essential to provide solid investment advice for Sangamo Therapeutics.
| Mean Return | 0.85 | Value At Risk | -11.29 | Potential Upside | 18.29 | Standard Deviation | 11.17 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Sangamo Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Sangamo Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sangamo Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sangamo Therapeutics backward and forwards among themselves. Sangamo Therapeutics' institutional investor refers to the entity that pools money to purchase Sangamo Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Advisers, Llc | 2023-12-31 | 2.1 M | Jpmorgan Chase & Co | 2023-12-31 | 1.4 M | Long Focus Capital Management, Llc | 2023-12-31 | 1.4 M | Northern Trust Corp | 2023-12-31 | 1.3 M | Charles Schwab Investment Management Inc | 2023-12-31 | 1.2 M | Millennium Management Llc | 2023-12-31 | 1.1 M | Gsa Capital Partners Llp | 2023-12-31 | 1.1 M | Assenagon Asset Management Sa | 2023-12-31 | 1 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 909 K | Blackrock Inc | 2023-12-31 | 14.1 M | Vanguard Group Inc | 2023-12-31 | 12.6 M |
Sangamo Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (62.0M) | 50.9M | 47.5M | (78.4M) | (55.2M) | (52.5M) | |
| Free Cash Flow | (165.1M) | 155.2M | (256.5M) | (243.8M) | (246.0M) | (233.7M) | |
| Depreciation | 9.6M | 13.4M | 17.6M | 20.6M | 22.2M | 23.3M | |
| Other Non Cash Items | 218K | (666K) | (6.4M) | (1.2M) | 153.8M | 161.5M | |
| Capital Expenditures | 20.7M | 14.7M | 23.3M | 20.2M | 21.2M | 22.2M | |
| Net Income | (95.4M) | (121.1M) | (178.3M) | (192.3M) | (257.8M) | (244.9M) | |
| End Period Cash Flow | 81.9M | 132.8M | 180.4M | 101.9M | 45.2M | 45.4M | |
| Change To Inventory | (1M) | 4.2M | (10.7M) | 7.7M | 8.8M | 9.3M | |
| Investments | (38.9M) | (256.2M) | 271.6M | 79.5M | 158.4M | 166.4M | |
| Change Receivables | (32.5M) | 31.3M | (103K) | 1.9M | 2.2M | 2.3M | |
| Change To Netincome | 19.4M | 25.9M | 32.9M | 31.7M | 36.4M | 38.2M |
Sangamo Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Sangamo Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Sangamo Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Sangamo stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.38 | |
β | Beta against NYSE Composite | 5.45 | |
σ | Overall volatility | 11.42 | |
Ir | Information ratio | 0.07 |
Sangamo Therapeutics Volatility Alert
Sangamo Therapeutics is displaying above-average volatility over the selected time horizon. Sangamo Therapeutics is a potential penny stock. Although Sangamo Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Sangamo Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Sangamo instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Sangamo Therapeutics Fundamentals Vs Peers
Comparing Sangamo Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Sangamo Therapeutics' direct or indirect competition across all of the common fundamentals between Sangamo Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Sangamo Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Sangamo Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Sangamo Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Sangamo Therapeutics to competition |
| Fundamentals | Sangamo Therapeutics | Peer Average |
| Return On Equity | -1.36 | -0.31 |
| Return On Asset | -0.18 | -0.14 |
| Profit Margin | (1.46) % | (1.27) % |
| Operating Margin | (24.76) % | (5.51) % |
| Current Valuation | 48.36 M | 16.62 B |
| Shares Outstanding | 207.5 M | 571.82 M |
| Shares Owned By Insiders | 7.70 % | 10.09 % |
| Shares Owned By Institutions | 56.50 % | 39.21 % |
| Number Of Shares Shorted | 11.41 M | 4.71 M |
| Price To Earning | (15.31) X | 28.72 X |
| Price To Book | 1.35 X | 9.51 X |
| Price To Sales | 0.63 X | 11.42 X |
| Revenue | 176.23 M | 9.43 B |
| Gross Profit | (138.6 M) | 27.38 B |
| EBITDA | (92.1 M) | 3.9 B |
| Net Income | (257.83 M) | 570.98 M |
| Cash And Equivalents | 315.72 M | 2.7 B |
| Cash Per Share | 2.02 X | 5.01 X |
| Total Debt | 38.1 M | 5.32 B |
| Debt To Equity | 0.13 % | 48.70 % |
| Current Ratio | 2.86 X | 2.16 X |
| Book Value Per Share | 0.47 X | 1.93 K |
| Cash Flow From Operations | (224.84 M) | 971.22 M |
| Short Ratio | 5.05 X | 4.00 X |
| Earnings Per Share | (1.48) X | 3.12 X |
| Target Price | 3.5 | |
| Number Of Employees | 405 | 18.84 K |
| Beta | 1.35 | -0.15 |
| Market Capitalization | 108.08 M | 19.03 B |
| Total Asset | 165.32 M | 29.47 B |
| Retained Earnings | (1.41 B) | 9.33 B |
| Working Capital | 46.6 M | 1.48 B |
| Current Asset | 212.58 M | 9.34 B |
Note: Acquisition by Scott Willoughby of 712500 shares of Sangamo Therapeutics subject to Rule 16b-3 [view details]
Sangamo Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Sangamo . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Sangamo Therapeutics Buy or Sell Advice
When is the right time to buy or sell Sangamo Therapeutics? Buying financial instruments such as Sangamo Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Total Stockholder Equity | 375.3M | 295.0M | 82.9M | 144.6M | Total Assets | 721.9M | 562.5M | 165.3M | 218.1M |
Use Investing Ideas to Build Portfolios
In addition to having Sangamo Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Moderate Funds Thematic Idea Now
Moderate Funds
Funds or Etfs that combine stocks, bonds and money market instruments to get modest capital appreciation over time. The Moderate Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Moderate Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sangamo Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Sangamo Stock analysis
When running Sangamo Therapeutics' price analysis, check to measure Sangamo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangamo Therapeutics is operating at the current time. Most of Sangamo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sangamo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangamo Therapeutics' price. Additionally, you may evaluate how the addition of Sangamo Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Sangamo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 1.01 | Quarterly Revenue Growth (0.93) | Return On Assets (0.18) | Return On Equity (1.36) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.